Todd M. Hobbs

Chief Medical Officer at Hepion Pharmaceuticals

Todd M. Hobbs was appointed as Chief Medical Officer in February of 2021. In this role, Dr. Hobbs helps lead Hepion's engagement with the U.S. Food and Drug Administration ("FDA"), global and national thought leaders, key policymakers, and professional associations.

Dr. Hobbs joined Hepion from Novo Nordisk Inc., one of the world's leading healthcare companies. His 16 years of progressive experience at Novo Nordisk includes positions ranging from field medical affairs leadership at the start of his corporate career through to his most recent role as North American Chief Medical Officer and Vice President. Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the medicine department for a large regional medical center in Kentucky. During his 10-year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.

Dr. Hobbs currently serves as a Member of the Board for the American Medical Group Association Foundation, the research foundation arm of the American Medical Group Association, in which he provides oversight for multiple clinical research initiatives. Dr. Hobbs earned his medical degree from the University of Louisville School of Medicine and has completed focused executive training at the University of Pennsylvania's Wharton School of Business.


  • Chief Medical Officer

    February 16, 2021 - present

View in org chart